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RELIABLE ASSESSMENT OF THEseparate and joint associationsof major blood lipids and apo-lipoproteins with the risk of
vascular disease is important for the de-
velopment of screening and therapeu-
tic strategies.1,2 Expert opinion is di-
vided about whether assessment of
apolipoproteinAI (apoAI) and apolipo-
protein B (apo B) should replace assess-
ment of high-density lipoprotein cho-
lesterol (HDL-C) and total cholesterol
levels in assessment of vascular risk.3-5
Althoughthere isagreementabout the
valueofreducinglow-densitylipoprotein
cholesterol (LDL-C or, approximately
analogously,non–high-density lipopro-
tein cholesterol [non–HDL-C]), uncer-
tainty persists about themerits ofmodi-
ficationormeasurementof triglycerides
orHDL-C.3Therearestronglypositiveepi-
demiological associationsof triglyceride
concentration with risk of vascular dis-
ease,6,7 but it is not clear to what extent
theserelationshipsdependoncholesterol
levels or vary with fasting state.
Similarly, although previous analy-
ses have generally reported inverse as-
sociations of HDL-C with risk of vas-
cular disease, many studies have not
investigated the extent to which they
depend on triglyceride concentra-
tion.8 The failure of torcetrapib has
raised questions about the value of rais-
ing HDL-C and highlighted the need to
characterizemore reliably the relation-
ship betweenHDL-C and vascular risk,
particularly at high HDL-C levels.9
Different uncertainties apply in re-
lation to the risk of ischemic stroke and
the cholesterol content of proathero-
genic lipoproteins. The reduction in is-
chemic stroke in randomized trials of
statins (whichprincipally lower LDL-C)
is remarkable in light of the weak epi-
demiological association reported be-
tween circulating LDL-C concentra-
tion and ischemic stroke,10,11 suggesting
the need for more powerful and de-
tailed prospective analyses of blood lip-
ids and stroke subtypes.
The objective of this report is to pro-
duce reliable estimates of the associa-
tions of major lipids and apolipopro-
teins in relation to coronary heart
disease (CHD) and ischemic stroke, in-
corporating adjustment for confound-
ing caused by other risk factors and cor-
rection for regression dilution.12
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Context Associations of major lipids and apolipoproteins with the risk of vascular
disease have not been reliably quantified.
Objective To assess major lipids and apolipoproteins in vascular risk.
Design, Setting, and Participants Individual records were supplied on 302 430
people without initial vascular disease from 68 long-term prospective studies, mostly
in Europe and North America. During 2.79 million person-years of follow-up, there
were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths,
2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes.
Main Outcome Measures Hazard ratios (HRs), adjusted for several conventional
factors, were calculated for 1-SD higher values: 0.52 loge triglyceride, 15 mg/dL high-
density lipoprotein cholesterol (HDL-C), 43 mg/dL non–HDL-C, 29 mg/dL apolipo-
protein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density
lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for
within-person variation and combined using meta-analysis.
Results The rates of CHD per 1000 person-years in the bottom and top thirds of
baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and
2.4 with HDL-C, and 2.3 and 6.7 with non–HDL-C. Adjusted HRs for CHD were 0.99
(95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50
(95% CI, 1.39-1.61) with non–HDL-C. Hazard ratios were at least as strong in par-
ticipants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI,
0.30-0.42) with a combination of 80 mg/dL lower non–HDL-C and 15 mg/dL higher
HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were
1.50 (95% CI, 1.38-1.62) with the ratio non–HDL-C/HDL-C, 1.49 (95% CI, 1.39-
1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non–HDL-C, and
1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic
stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with
HDL-C, and 1.12 (95% CI, 1.04-1.20) with non–HDL-C.
Conclusion Lipid assessment in vascular disease can be simplified by measurement
of either total and HDL cholesterol levels or apolipoproteins without the need to fast
and without regard to triglyceride.
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METHODS
Study Design
Detailsofstudyselection,datacollection,
and harmonization procedures of the
Emerging Risk Factors Collaboration
(ERFC)havebeendescribedpreviously.13
Onehundred twelveprospective studies
of cardiovascular risk factors, involving
a total of 1.2 million participants, have
shared individual records in the ERFC
(eFigure 1, available at http://www.jama
.com). These studies were approxi-
mately population-based (ie, did not se-
lect participants on the basis of having
previous cardiovascular disease); re-
corded cause-specific mortality or vas-
cular morbidity using accepted crite-
ria; and had accrued more than 1 year
of follow-up. eTable 1 lists details of the
68 studies—involving a total of 302430
participants without any known his-
tory of CHD (ie, myocardial infarction
[MI], angina, or stroke, whichwere de-
fined in each study) at the initial (“base-
line”) examination—that had com-
plete information at baseline on total
cholesterol,HDL-C, and triglyceride lev-
els and several conventional risk fac-
tors (ie, age, sex, smoking status, his-
tory of diabetes mellitus, systolic blood
pressure, body mass index). Refer-
ences for studies in eTable 1 are in eAp-
pendix 1 and in a previously published
reference list.13 Twenty-two studieswith
91 307 participants had information on
the preceding variables plus apo B and
apo AI, and 8 studies with 44 234 par-
ticipants had directly measured LDL-C
values. The AMORIS study provided
data for the ERFC, but it could not be
incorporated into the current analyses
becauseAMORIS did notmeasure base-
line levels of HDL-C, blood pressure,
smoking, bodymass index, or diabetes.14
All but1 studyusedenzymaticmeth-
ods to assay triglyceride, and all but 2
studiesusedprecipitationmethodstoas-
sayHDL-C(eTable2).For assayof apo-
lipoproteins, 16 studies used immuno-
turbidimetry or nephelometry, 4 used
immunoradiometric assays, 1 used im-
munoelectrophoresis,and1involvedim-
munochemical methods. For assay of
LDL-C, 4 studies used ultracentrifuga-
tion, 2useddirect homogeneousmeth-
ods, 1used chemical precipitation, and
1usedelectrophoresis. In registering fa-
tal outcomes, all contributing studies
usedcoding fromthe InternationalClas-
sification of Diseases to at least 3 digits
and ascertainment was based on death
certificates. Fifty-two of 68 contribut-
ingstudiesalsoinvolvedmedicalrecords,
autopsy findings, andother supplemen-
tarysourcestohelpclassifydeaths.Sixty-
twostudiesused standarddefinitionsof
MIbasedonWorldHealthOrganization
criteria. Fifty-six studies reporteddiag-
nosis of strokes on the basis of typical
clinical features and characteristic
changes on brain imaging, and all at-
tempted toprovideattributionof stroke
subtype.
Statistical Analyses
Non–HDL-C(calculatedby subtraction
of HDL-C from total cholesterol, yield-
ing a measure that encompasses low–,
intermediate–, andvery–low-density li-
poprotein cholesterol) was used as the
principalmarker of cholesterol content
in proatherogenic lipoproteins in order
to avoid the biases that may arise when
using LDL-C values estimated by the
Friedewaldformula15(eAppendix2).Tri-
glyceridewaslogetransformedtoimprove
its normality. Details of the statistical
methods have been described previ-
ously.16TheprimaryoutcomewasCHD
(ie, first-ever MI or fatal CHD). Analy-
ses involveda2-stage approachwith es-
timatesofassociationcalculatedseparately
within each studybeforepooling across
studiesbyrandom-effectsmeta-analysis.
For the 64 studies analyzed as pro-
spective cohort studies, hazard ratios
(HRs) were calculated using Cox pro-
portionalhazard regressionmodels strati-
fied by sex (and, where appropriate, by
trial group).Theproportionalhazardsas-
sumption was satisfied for each lipid in
each of the studies. Participants contrib-
uted only their first nonfatal outcomeor
death recorded at age 40 years or older
(ie, deaths preceded bynonfatal CHDor
stroke were not included in the main
analyses). For the 4 contributing indi-
vidually matched nested case-control
studieswithin prospective cohorts, odds
ratios were calculated using condi-
tional logistic regression models. Odds
ratios approximated HRs because these
studies selected cases and controls con-
currently and matched for age and sex.
Tohelpcharacterizeshapesofassocia-
tions,study-specificHRscalculatedwithin
overall quantiles of baseline lipid levels
werepooledonthe logscalebymultivar-
iaterandom-effectsmeta-analysisandplot-
ted against pooled mean usual levels of
the relevant lipid marker within each
quantile.Ninety-fivepercentconfidence
intervals (CIs) were estimated from the
variancesthatreflect theamountof infor-
mation underlying each group (includ-
ing thereferencegroup).Asassociations
wereapproximatelylog-linear,regression
coefficientswerecalculatedtoestimatethe
HRsassociatedwith1-SDhigherbaseline
valuesofeachlipid:0.52loge triglyceride,
15mg/dLHDL-C,43mg/dLnon–HDL-C
(and, insubsets,29mg/dLapoAI,29mg/
dLapoB,and33mg/dL fordirectlymea-
sured LDL-C). (To convert HDL-C and
LDL-C to mmol/L, multiply by 0.0259;
toconvert triglycerides tommol/L,mul-
tiply by 0.0113.)
Hazard ratios were adjusted progres-
sively for age, sex, systolic blood pres-
sure, smoking status, history of dia-
betes, bodymass index, and lipidmea-
sures, with the evidence of association
indicated by the Wald 2 statistic and
heterogeneity between studies as-
sessed by the I2 statistic.17 Investiga-
tion of effect modification was quanti-
fied by formal tests of interaction.
Diversity at the study level was inves-
tigated by grouping studies by re-
corded characteristics and by meta-
regression.
We corrected for bias caused by vari-
ability in levels of both lipids and poten-
tial confounding factors. Regression di-
lution ratioswere obtainedby regressing
serialmeasurementsof risk factors, taken
fromup to89073participants (mean in-
terval, 4.9 years), onbaseline levels of the
relevant characteristic and duration of
follow-up. Correction for within-
person variation in risk factors was
achieved by use of conditional expecta-
tions of long-term average levels (“usual
levels”) of these risk factors, whichwere
predicted from these regression calibra-
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tion models and used in the estimation
of HRs, as described previously.12,18
Analyses involved Stata software, re-
lease 10 (StataCorp, College Station,
Texas); 2-sidedP values and95%CIs are
presented. This study was approved by
the Cambridgeshire ethics review com-
mittee and was conducted and ana-
lyzed independently from its funders.
RESULTS
Mean(SD)ageatentryofparticipantswas
59(8)years,43%werewomen,60%were
in western Europe, and 32% in North
America (eTable3).During2.79million
person-yearsat risk(median,6.1years to
firstoutcome), therewere,countingonly
first-ever outcomes, 8857 nonfatal MIs,
3928CHDdeaths,2534ischemicstrokes,
513 hemorrhagic strokes, and 2536 un-
classified strokes (eTable 4).Mean (SD)
levels of loge triglyceride, HDL-C, and
non–HDL-C were each broadly similar
across studies (eTable1). Loge triglycer-
ide, HDL-C, and non–HDL-Cwere cor-
relatedwithoneanother,withparticularly
strong correlations of non–HDL-Cwith
apoBanddirectlymeasuredLDL-C,and
Figure 1. Hazard Ratios for Coronary Heart Disease or Ischemic Stroke Across Quantiles of Usual Triglyceride, HDL-C, and Non–HDL-C Levels
Adjusted for age and sex only
Further adjusted for several risk factors
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Analyses for coronary heart disease were based on 302 430 participants (involving 12 785 cases) from 68 studies. Analyses for ischemic stroke were based on 173 312
participants (involving 2534 cases) from 32 studies. Regression analyses were stratified, where appropriate, by sex and trial group. Values with further adjustments
were adjusted for age, systolic blood pressure, smoking status, history of diabetes mellitus, and body mass index; furthermore, analyses of loge triglyceride were ad-
justed for high-density lipoprotein cholesterol (HDL-C) and non–HDL-C levels, analyses of HDL-C were adjusted for non–HDL-C and loge triglyceride levels, and analy-
ses of non–HDL-C were adjusted for HDL-C and loge triglyceride levels. Studies with fewer than 10 cases were excluded from analysis. Sizes of data markers are
proportional to the inverse of the variance of the hazard ratios. The y-axes are shown on a log scale. The x-axes for triglyceride are shown on a log scale. Referent
groups are lowest quantiles for triglyceride and non–HDL-C and highest quantiles for HDL-C. Error bars indicate 95% confidence intervals.
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of HDL-Cwith apoAI (eTable 3). Serial
measurements yielded age- and sex-
adjustedregressiondilutionratiosof0.63
(95%CI,0.60-0.67) for loge triglyceride,
0.69(95%CI,0.64-0.74)forHDL-C,0.60
(95%CI,0.54-0.65)fornon–HDL-C,0.57
(95%CI,0.46-0.69)forapoAI,0.61(95%
CI, 0.47-0.75) for apo B, and 0.64 (95%
CI,0.57-0.71)fordirectlymeasuredLDL-
C.TheratesofCHDper1000person-years
in the bottom and top thirds of baseline
lipiddistributions, respectively,were2.6
and6.2withtriglyceride,6.4and2.4with
HDL-C,and2.3and6.7withnon–HDL-
C. In analyses adjusted for age and sex
only,eachlipidstudiedwasapproximately
log-linearlyassociatedwithCHDrisk,with
possibleattenuationatveryhighHDL-C
and at low non–HDL-C concentration
(FIGURE 1).
Triglyceride
The HR for CHDwith triglyceride was
1.37 (95% CI, 1.31-1.42) after adjust-
ment for nonlipid risk factors, but it was
reduced to 0.99 (95%CI, 0.94-1.05) af-
ter further adjustment for HDL-C and
non–HDL-C (theWald2 reduced from
214 to 0) (eTable 5 andFigure 1). There
was modest heterogeneity among the
contributing studies (I2=35%; 95%CI,
12%-52%). AdjustedHRs forCHDwere
essentially null under a range of cir-
cumstances, including by sex (HRs of
0.97 [95% CI, 0.91-1.03] in men and
1.06 [95% CI, 0.96-1.16] in women)
and by fasting status (HRs of 1.02 [95%
CI, 0.95-1.09] in peoplewho fasted and
0.92 [95%CI, 0.82-1.03] in peoplewho
did not fast) (eFigure 2). There was,
however, an apparently positive asso-
ciation at lower systolic blood pres-
sure. The adjusted HR was 1.02 (95%
CI, 0.94-1.11) for ischemic stroke
(eTable 5 and Figure 1), 1.04 (95%CI,
0.82-1.32) for hemorrhagic stroke, and
1.03 (95% CI, 0.94-1.13) for unclassi-
fied stroke.
High-Density Lipoprotein
Cholesterol
The HR for CHDwith HDL-C was 0.71
(95%CI, 0.68-0.75) after adjustment for
nonlipid risk factors, and it was 0.78
(95%CI, 0.74-0.82) after further adjust-
ment for non–HDL-C and loge triglyc-
eride (theWald 2 reduced from 149 to
84) (eTable 5 and Figure 1). There was
modest heterogeneity among the con-
tributing studies (I2=40%; 95%CI, 20%-
55%). The HR for CHD was stronger at
younger ages and at lower systolic blood
pressure, but it did not vary impor-
tantly by sex, other lipid fractions, dia-
betes, or body mass index (eFigure 2).
Findings did not varymaterially in sub-
analyses that additionally adjusted for
C-reactive protein or fibrinogen concen-
tration (eTable 6) or alcohol consump-
tion (or that excluded alcohol abstain-
ers). Hazard ratios were 0.79 (95% CI,
0.74-0.84) inparticipantswho fastedand
0.75 (95% CI, 0.68-0.83) in partici-
pantswhodid not fast. The adjustedHR
for ischemic stroke was 0.93 (95% CI,
0.84-1.02) (eTable 5 andFigure 1),with
modest heterogeneity among the con-
tributing studies (I2=27%; 95% CI, 0%-
53%)(eTable5).AdjustedHRswere1.09
(95% CI, 0.92-1.29) for hemorrhagic
stroke and 0.87 (95%CI, 0.80-0.94) for
unclassified stroke.
Non–High-Density Lipoprotein
Cholesterol
TheHR for CHDwith non–HDL-Cwas
1.56 (95% CI, 1.47-1.66) after adjust-
ment for nonlipid risk factors, and itwas
1.50 (95%CI,1.39-1.61) after further ad-
justment for HDL-C and loge triglycer-
ide (the Wald 2 reduced from 229 to
122) (eTable 5 andFigure 1). Therewas
considerable heterogeneity among the
contributing studies (I2=73%; 95% CI,
66%-79%), partly explainedbymore ex-
treme HRs in participants who did not
fast vs those who fasted (1.72 [95% CI,
1.51-1.95] vs 1.41 [95%CI, 1.30-1.53];
P=.01) and in studies with serum than
thosewith other types of blood samples
(1.60 [95%CI, 1.47-1.74] vs 1.31 [95%
CI, 1.17-1.47];P=.008) (eFigure 2). The
HR for CHD was slightly stronger at
younger ages (although it remained
strong even at older ages) andmore ex-
treme at lower systolic blood pressure.
Hazard ratios for CHD did not vary im-
portantlyby sex, levels of other lipid frac-
tions, diabetes, or body mass index
Figure 2. Hazard Ratios for Coronary Heart Disease Across Fifths of Non–HDL-C by Levels of
HDL-C and Fifths of HDL-C by Levels of Non–HDL-C
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Analyses were based on 302 430 participants (involving 12 785 cases) from 68 studies. Median values in the Emerg-
ing Risk Factors Collaboration were 50 mg/dL for high-density lipoprotein cholesterol (HDL-C) and 169 mg/dL
for non–HDL-C. Regression analyses were stratified, where appropriate, by sex and trial group and adjusted for
age, systolic blood pressure, smoking status, history of diabetes mellitus, body mass index, and loge triglyceride
levels. Studies with fewer than 10 cases were excluded from analysis. Sizes of data markers are proportional to the
inverse of the variance of the hazard ratios. The y-axes are shown on a log scale. Referent groups are lowest fifth
of non–HDL-C in the higher level of HDL-C and highest fifth of HDL-C in the lower level of non–HDL-C. Lines are
fitted by log-linear regression of log hazard ratios on mean levels. Error bars indicate 95% confidence intervals.
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(eFigure 2). In the subset of partici-
pants with available measurements, the
adjusted HRs for CHD were 1.38 (95%
CI, 1.09-1.73) with directly measured
LDL-C and 1.42 (95% CI, 1.06-1.91)
with non–HDL-C (eTable 7). The ad-
justed HR for ischemic stroke was 1.12
(95% CI, 1.04-1.20) with non–HDL-C,
about 4 timesweaker than that for CHD
(eTable 5 and Figure 1). Adjusted HRs
were 0.98 (95%CI, 0.82-1.17) for hem-
orrhagic stroke and 1.01 (95%CI, 0.93-
1.09) for unclassified stroke.
Combined Lipid Analyses
and Apolipoproteins
Hazard ratios for CHD with non–
HDL-C were generally similar at differ-
ent HDL-C levels and vice versa
(FIGURE 2). The HR for CHD was 0.35
(95% CI, 0.30-0.42) with a combina-
tion of 15mg/dL higher HDL-C and 80
mg/dL lower non–HDL-C, alterations
that are attainable with available lipid-
lowering agents.19,20 The HR was not
materially changed by addition of in-
formation on triglyceride. Non–
HDL-C and apo B each had very simi-
lar shape andmagnitude of associations
with CHD, as did HDL-C and apo AI
(FIGURE 3 and eTable 8). Hazard ra-
tios for CHDwere 1.50 (95% CI, 1.38-
1.62) with the ratio of non–HDL-C/
HDL-C (which is statistically equivalent
to the ratio of total cholesterol to
HDL-C) and 1.49 (95% CI, 1.39-1.60)
with the rat io of apo B/apo AI
(eTable 8). For ischemic stroke, there
were also similar findings with choles-
terol levels and apolipoproteins.
Qualitatively similar results to those
reported here were observed in analy-
ses that used fixed-effect models
(eFigure 3), compared larger vs smaller
studies, ignored regression dilution, re-
placed non–HDL-C with total choles-
terol, included fatal outcomes with-
out censoring previous nonfatal
outcomes, and omitted the 44 108 par-
ticipants from clinical trials (eFigure 2).
COMMENT
The current analysis of more than
300 000 people has demonstrated that
lipid assessment in vascular disease can
be simplified by measurement of either
cholesterol levels or apolipoproteins
without the need to fast andwithout re-
gard to triglyceride. This conclusion de-
rives from several findings. First, HRs
with non–HDL-C and HDL-C were
nearly identical to those seen with apo
B and apo AI. This finding suggests that
current discussions about whether to
measure cholesterol levels or apolipo-
proteins in vascular risk assessment
should hinge more on practical consid-
erations (eg, cost, availability, and stan-
dardization of assays) than onmajor dif-
ferences in strength of epidemiological
associations. Second, HRs for vascular
disease with lipid levels were at least as
strong in participants who did not fast
as in those who fasted. Third, HRs were
similar with non–HDL-C as with di-
rectlymeasured LDL-C. Finally, in con-
trast with previous findings based on
much less data, triglyceride concentra-
tionwas not independently relatedwith
CHD risk after controlling for HDL-C,
non–HDL-C, andother standard risk fac-
tors, including null findings in women
and under nonfasting conditions.21,22
Hence, for population-wide assessment
of vascular risk, triglyceride measure-
ment provides no additional informa-
tion about vascular risk given knowl-
edge of HDL-C and total cholesterol
levels, although there may be separate
reasons tomeasure triglyceride concen-
tration (eg, prevention of pancreatitis).
Concentrations of HDL-C and non–
HDL-Cwereeachstronglyassociated—
in opposite directions—with CHD risk
in an approximately log-linearmanner.
Incontrastwiththenull triglyceridefind-
ings after adjustment,HDL-Candnon–
HDL-C were largely independent from
each other on a multiplicative scale, as
well as from triglyceride concentration
and other risk factors. Hence, whereas
Figure 3. Hazard Ratios for Coronary Heart Disease Across Fifths of Usual Lipids or
Apolipoproteins
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Analyses were based on 91 307 participants (involving 4499 cases) from 22 studies. Regression analyses were strati-
fied, where appropriate, by sex and trial group and adjusted for age, systolic blood pressure, smoking status, history
of diabetes mellitus, and body mass index; furthermore, analyses of non–HDL-C were adjusted for HDL-C and loge
triglyceride, analyses of apolipoprotein B (apo B) were adjusted for apolipoprotein AI (apo AI) and loge triglyceride,
analyses of HDL-C were adjusted for non–HDL-C and loge triglyceride, and analyses of apo AI were adjusted for
apo B and loge triglyceride. Studies with fewer than 10 cases were excluded from analysis. Sizes of data markers are
proportional to the inverse of the variance of the hazard ratios. Referent groups are lowest fifths. Lines are fitted by
first-degree fractional polynomial regression of log hazard ratios on mean SD score. Error bars indicate 95% con-
fidence intervals. The y-axis is shown on a log scale. The x-axis is shown on a Z-transformed scale.
LIPIDS, APOLIPOPROTEINS, AND RISK OF VASCULAR DISEASE
©2009 American Medical Association. All rights reserved. (Reprinted) JAMA, November 11, 2009—Vol 302, No. 18 1997
Downloaded From: http://jama.jamanetwork.com/ by a Imperial College London User  on 08/23/2016
prevailingtherapeuticstrategies focuson
lowering of LDL-C (or, approximately
analogously, non–HDL-C), the current
findings suggest that therapydirectedat
HDL-Caswell asnon–HDL-Cmaygen-
erate substantial additional benefit. For
example,CHDriskisapproximatelytwo-
thirds lower in people with 15 mg/dL
higherHDL-Cand80mg/dLlowernon–
HDL-C, which are alterations that are
attainablewith,say,extended-releasenia-
cin plus a potent statin.19,20 Long-term
randomizedtrialsofsuchlipid-modifying
regimens are therefore needed to test
this epidemiologically expected risk re-
duction.23-25
Because associations of higher non–
HDL-C concentration with CHD are
similar at both higher and lowerHDL-C
concentrations, the absolute benefits of
lowering LDL-C are likely to be greater
if HDL-C concentration is low (orwhen
absolute risk is high for some other rea-
son). While the current findings can-
not confirmor refute causality for either
triglyceride or HDL-C concentration,
they encourage large CHD studies of
therapies and genotypes that specifi-
cally affect each of these lipid measures
to help judge etiological relevance.23-29
Observational analyses focused on eti-
ology should ideally allow for the pos-
sibility of disparate associations of dif-
ferent non–HDL-C components with
vascular risk, which requires informa-
tion on each type of low–, intermedi-
ate–, and very–low-density lipoprotein
cholesterol (such information was not
available inmost studies contributing to
the current analysis).
Hemorrhagic strokewas unrelated to
any of the lipids studied here. Only pro-
atherogenic lipids appeared to be as-
sociated with risk of ischemic stroke,
albeit modestly. Indeed, the current
study found anHR for CHDwith non–
HDL-C about 4 times greater than that
for ischemic stroke. Because statin
medications reduce risk of both CHD
and ischemic stroke to a similar ex-
tent,10 the quantitative discrepancy ob-
served between epidemiological asso-
ciations of non–HDL-Cwith CHD and
ischemic stroke is striking.30 To char-
acterize this risk in more detail, stud-
ies are needed that can subtype the di-
verse etiologies for ischemic stroke.31
Given the essentially null associations
observed between HDL-C concentra-
tion and stroke risk, considerable loss
of statistical powermay result from in-
clusion of stroke in primary outcomes
of HDL-C–raising trials23,25,29 (unless
similar effects are observed to those in
the previous trials of statin).
There was some heterogeneity in the
findings, but thebroad consistencyof re-
sults across 68 studies in 21 countries
supports their generalizability. Con-
founding was minimized by adjust-
ment of HRs for long-term average lev-
els of risk factors based on more than
89000 serialmeasurements.As the loga-
rithm of triglyceride concentration had
a regression dilution ratio comparable
with those of other lipidmeasures, such
variability cannot account for the differ-
entHRs forCHD thatwere seenwith the
different lipidmeasures.Thecurrentpro-
spective data contrast sharplywith those
of some large retrospective case-control
studies that reported that apolipopro-
teins have much stronger associations
with CHD risk than cholesterol lev-
els.32,33 Case-control studies of acuteMI
may be liable to distortion of lipid lev-
els by recent infarction, a potential bias
that is minimized by prospective analy-
ses of participantswithout cardiovascu-
lar disease at baseline.32,33 It remains un-
clear whether some residual artifact
explains the apparent flattening of asso-
ciations seen in the present analyses
withCHDat very highHDL-Cor at very
low non–HDL-C concentrat ion
(whereas, by contrast, randomized statin
trials indicate that LDL-C lowering be-
low 80 mg/dL continues to lower CHD
risk10,34).
CONCLUSION
Lipid assessment in vascular disease can
be simplified bymeasurement of either
total andHDL cholesterol levels or apo-
lipoproteins without the need to fast
and without regard to triglyceride.
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